Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630601 | 0.88 | HTR7 (0.45) | TSHRALDH1A1GLAPOLBDRD2 | |
| SCHEMBL2400927 | 0.86 | HRH3 (0.46) | TSHRALDH1A1HTR7TP53 | |
| SCHEMBL1241268 | 0.86 | HRH3 (0.46) | TSHRALDH1A1HTR7TP53 | |
| SCHEMBL5629084 | 0.85 | SMN1; SMN2 (0.47) | TSHRALDH1A1HTR7TP53 | |
| Water SCHEMBL16161850 | 0.85 | HRH3 (0.46) | TSHRALDH1A1HTR7TP53 | |
| SCHEMBL14244325 | 0.85 | ESR1 (0.46) | TSHRALDH1A1PDE5AMETAP2HTT | |
| SCHEMBL5632462 | 0.85 | HTR7 (0.42) | TSHRALDH1A1GLAPOLBHTR2C | |
| SCHEMBL2456982 | 0.85 | ESR1 (0.46) | TSHRALDH1A1PDE5AMETAP2HTT | |
| SCHEMBL5630748 | 0.85 | HTR7 (0.42) | TSHRALDH1A1HTR7TP53 | |
| SCHEMBL2403756 | 0.84 | PNMT (0.53) | TSHRALDH1A1DRD2DRD3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748615-B2 | Process for the preparation of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-20130123302-A1 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123302-A1 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N--1,2,3,4-TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SULT1E1, SULT2A1, STS | TSHR 3886/4885ALDH1A1 1389/4885GLA 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.